Major Breakthrough in the Fight against Cervical Cancer Presented at EUROGIN in Prague
2 Pages
English

Major Breakthrough in the Fight against Cervical Cancer Presented at EUROGIN in Prague

Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

Description

Major Breakthrough in the Fight against Cervical Cancer Presented at EUROGIN in Prague PR Newswire MENLO PARK, California, July 11, 2012 MENLO PARK, California, July 11, 2012 /PRNewswire/ -- Approximately 510,000 cases of cervical cancer are reported each year around the world, making it the second leading cause of cancer deaths among women worldwide. Yet, cervical cancer is treatable — and often curable — when detected in its early stages. IncellDx, a California-based research company, has introduced a new testing methodology called HPV OncoTect that measures a woman's increased risk for future development of cervical cancer with remarkable accuracy. Virtually all cases of cervical cancer are caused by specific types of human papillomavirus (HPV) and current testing methods detect only the presence and type of HPV infection and cellular abnormalities caused by the virus. OncoTect goes further to not only detect cellular transformation caused by persistent HPV infection, but also quantify the cancer causing genes found in the cells that is the necessary precursor to the development of cervical cancer. The new test was the focus of two independent clinical studies that sought to compare the performance of OncoTect against other commercially available tests.

Subjects

Informations

Published by
Reads 38
Language English
Major Breakthrough in the Fight against
Cervical Cancer Presented at EUROGIN in
Prague
PR Newswire
MENLO PARK, California, July 11, 2012
MENLO PARK, California
,
July 11, 2012
/PRNewswire/ -- Approximately 510,000
cases of cervical cancer are reported each year around the world, making it
the second leading cause of cancer deaths among women worldwide. Yet,
cervical cancer is treatable — and often curable — when detected in its early
stages. IncellDx, a
California
-based research company, has introduced a new
testing methodology called
HPV OncoTect
that measures a woman's
increased risk for future development of cervical cancer with remarkable
accuracy.
Virtually all cases of cervical cancer are caused by specific types of human
papillomavirus (HPV) and current testing methods detect only the presence and
type of HPV infection and cellular abnormalities caused by the virus.
OncoTect
goes further to not only detect cellular transformation caused by persistent
HPV infection, but also quantify the cancer causing genes found in the cells that
is the necessary precursor to the development of cervical cancer.
The new test was the focus of two independent clinical studies that sought to
compare the performance of
OncoTect
against other commercially available
tests. The results of these studies is being introduced to the international
medical community at EUROGIN 2012, one of the largest global forums for the
review of current scientific developments in the field of cervical cancer and
human papillomavirus related diseases.
The first study, conducted in
Greece
, evaluated the specificity of
HPV
OncoTect
against the commonly utilized HPV DNA test. After analyzing 4,000
cervical cell samples, researchers found that
OncoTect
significantly increases
specificity for high grade cervical disease compared to HPV DNA genotyping
while maintaining the sensitivity of commonly used HPV DNA tests. If a test has
high specificity, a positive result from the test means a high probability of the
presence of disease.
Italian researchers conducted a second study to compare
OncoTect
with a
competitive product called NucliSens EasyQ . Their results showed that while
NucliSens EasyQ did identify the presence of cancer causing genes, the clinical
significance of the findings are limited because it does not measure the extent
of the cellular changes that led to disease in addition to showing lower
sensitivity compared to OncoTect.
IncellDx also has been invited to present new data at EUROGIN 2012 on the
next generation of the
HPV OncoTect
test – called
OncoTect 3Dx
, which uses
the newest cancer screening technology that incorporates morphology of slides
with molecular biomarkers in a single high throughput assay thus eliminating
ambiguous pap results. The new technology further improves the test's ability
to distinguish between benign infection and the cell changes that can lead to
the development of cancer. In addition, this technology does not rely on a glass
slide, thus reducing the cost and time taken to complete the test significantly.
More than 2,000 healthcare professionals are attending EUROGIN 2012, held
this year in
Prague, Czech Republic
, from July 8-11. The event seeks to
accelerate the translation of scientific discoveries into day-to-day medical
practice.
Until now, HPV diagnostic testing could identify only the presence and type of
HPV, but could not predict if the infection would clear up or likely progress to
cancer.
OncoTect
is an important diagnostic tool, helping doctors know when
more aggressive testing is needed – and also to feel confident when "wait and
see" is the best approach. Traditionally, when a woman tests positive for high
risk HPV infection, her doctor performs a colposcopy, a magnified examination
of the cervix in which biopsy samples are taken.
OncoTect
will help determine
when colposcopies are medically unnecessary.
OncoTect
is
an important breakthrough for women because:
It accurately detects the presence of cell changes due to persistent HPV infection,
enabling physicians to distinguish between benign infection and precancerous disease.
An accurate diagnosis will reduce unnecessary testing
Sample cells are collected from the cervix in the same manner as a pap test with
virtually no discomfort.
It can be administered during one office visit -- often at the same time as a pap test.
The test has a fast turn-around time, similar to an HPV DNA test.
About IncellDx, Inc.
IncellDx, Inc. is a molecular diagnostics company dedicated to the detection
and monitoring of life threatening diseases such as cervical cancer, breast
cancer, HIV/AIDs, hepatitis, and organ transplant rejection.